Merrill Lynch Downgrades Teva Pharma to Hold

By Ryan Adsit

In a report released today, Sumant Kulkarni from Merrill Lynch downgraded Teva Pharma (NYSE: TEVA) to Hold. The company’s shares closed last Friday at $40.24, close to its 52-week low of $37.82.

According to, Kulkarni is a 1-star analyst with an average return of -4.5% and a 32.6% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Cynapsus Therapeutics, Impax Laboratories, and Perrigo Company.

Currently, the analyst consensus on Teva Pharma is Strong Buy and the average price target is $67.60, representing a 68.0% upside.

In a report issued on November 4, HSBC also downgraded the stock to Hold.

Based on Teva Pharma’s latest earnings report from March 31, the company posted quarterly revenue of $4.81B and quarterly net profit of $636M. In comparison, last year the company earned revenue of $4.82B and had a net profit of $103M.

Teva Pharmaceutical Industries Ltd. engages in the provision of pharmaceutical services. It operates through the following two segments: Generic and Specialty Medicine. The Generic segment includes chemical and therapeutic equivalents of originator medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. The Specialty Medicine segment includes several franchises, most significantly core therapeutic areas of CNS medicines. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.